stockrow
Friday 6 November 2026
Export RVMD’s income statement to Excel — free account
Revolution Medicines, Inc.
RVMD Healthcare Biotechnology
Revolution Medicines, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $11.6 million, down 67.3% from fiscal 2022.
- Revenue
- +1,188.7%
- EPS
- −18.0%
- Free cash flow
- −99.1%
- Total debt
- +322.7%
Quarter to September 2026, against a year earlier
193.65
16.00
+9.01%
Follow RVMD
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 4 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | 0.00 |
P/S ratio |
— | — | — | 210.96 | |
P/FCF ratio |
— | — | — | 0.00 | |
P/Operating CF |
— | — | — | (106.15) | |
P/B ratio |
— | — | — | 18.37 | |
Price to Tangible BV |
— | — | — | 18.92 | |
EV/Sales |
— | — | — | 198.45 | |
EV/EBITDA |
— | — | — | 0.00 | |
EV/Operating CF |
— | — | — | (29.00) | |
EV/FCF |
— | — | — | (28.81) | |
Quick Ratio |
6.97 | 6.59 | 11.12 | 7.68 | |
Current Ratio |
7.14 | 6.80 | 11.38 | 8.36 | |
Net Debt/EBITDA |
4.86 | 3.67 | 5.75 | 0.00 | |
Debt/Assets |
11.40% | 12.45% | 23.96% | 0.00% | |
Debt/Equity |
0.16 | 0.19 | 0.40 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.06 | |
Operating CF/Net income |
0.75 | 0.78 | 0.60 | 1.02 | |
Capex/Depreciation |
(13.01) | (1.17) | (13.69) | 0.00 | |
Interest Coverage |
(30.30) | (36.50) | (21.24) | (11.04) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 211.12% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.03 | 0.03 | 0.02 | 0.02 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 31.70% | |
Graham Net Nets |
— | — | — | 0.05 | |
Graham Number |
— | — | — | 0.00 | |
Earnings Yield |
— | — | — | (4.44%) | |
Free Cash Flow Yield |
— | — | — | (3.27%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.92 | |
Operating CF per Share |
(1.44) | (1.79) | (1.84) | (1.93) | |
Capex per Share |
(0.01) | (0.01) | (0.01) | (0.02) | |
Free Cash Flow per Share |
(1.45) | (1.80) | (1.85) | (1.95) | |
Cash per Share |
10.65 | 9.63 | 18.67 | 16.99 | |
Shareholders Equity per Share |
8.58 | 7.57 | 12.36 | 11.17 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
8.58 | 7.57 | 12.36 | 11.17 | |
Free Cash Flow |
(276.16) | (355.70) | (389.60) | (419.35) | |
Working Capital |
1,784.61 | 1,678.31 | 3,674.28 | 3,501.03 | |
Capital Expenditures |
(1.92) | (1.54) | (2.29) | (3.70) | |
Net Current Asset Value |
1,351.83 | 1,214.09 | 2,311.31 | 2,074.69 | |
EV/EBIT |
— | — | — | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.02 | |
Price to Operating Income |
— | — | — | 0.00 | |
| Other line items | |||||
Average Payables |
59.52 | 64.02 | 72.59 | 87.75 | |
Average Assets |
2,456.40 | 2,309.55 | 3,376.42 | 3,277.72 | |
Average Common Equity |
1,948.25 | 1,789.03 | 2,235.80 | 1,999.20 |
Columns are period end dates · fundamentals updated 4 Nov 2026